Trials for 3rd booster dose of Covaxin at AIIMS

The clinical trials of the third dose of indigenous Covid-19 vaccine, the COVAXIN, as a booster dose, six months after administering the second dose, began in All India Institute of Medical Science, Delhi today.

“Booster dose simply means boosting the immune response after completing primary vaccination if you feel that after sometimes may be 6 months or 8 month or even after one year, that your immune response is going down & you want to boost your immunity, this may work or this may not work,” Dr. Sanjay Rai, Principal Investigator of COVAXIN trials in AIIMS, Delhi said.

The study will be conducted on 190 participants who were already vaccinated with COVAXIN (as part of the phase 2 trial) six months ago. There will be nine sites where the study for booster dose will be in participants between the age group of 18 to 55 years.

The COVAXIN manufacturer, Bharat Biotech India Limited got the subject expert committee (SEC) permission for carrying out the booster dose trials. Prag News